albuterol has been researched along with Cryptogenic Fibrosing Alveolitis in 1 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Usmani, OS | 1 |
| Biddiscombe, MF | 1 |
| Yang, S | 1 |
| Meah, S | 1 |
| Oballa, E | 1 |
| Simpson, JK | 1 |
| Fahy, WA | 1 |
| Marshall, RP | 1 |
| Lukey, PT | 1 |
| Maher, TM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study of the Pharmacokinetics and Deposition of Inhaled Salbutamol in Patients With Idiopathic Pulmonary Fibrosis (TOPICAL-IPF)[NCT01457261] | Phase 1 | 10 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for albuterol and Cryptogenic Fibrosing Alveolitis
| Article | Year |
|---|---|
The topical study of inhaled drug (salbutamol) delivery in idiopathic pulmonary fibrosis.
Topics: Administration, Inhalation; Administration, Topical; Aged; Aged, 80 and over; Albuterol; Bronchodila | 2018 |